目的:观察益心利水方联合重组人脑利钠肽治疗急性心力衰竭的临床疗效.方法:选取2021 年6 月至2023 年6 月在郑州市第九人民医院老年医学科接受治疗的急性心力衰竭患者82 例,按照随机数字表法分为对照组和观察组,每组 41 例.对照组给予重组人脑利钠肽静脉注射治疗,观察组在对照组治疗的基础上给予自拟益心利水方治疗.观察两组患者治疗前后心功能[左心室射血分数(left ventricular ejection fraction,LVEF)、左心室舒张末期内径(left ventricular end diastolic dimension,LVEDD)]、肌酸激酶同工酶(creatine kinase isoenzymes-MB,CK-MB)、超敏肌钙蛋白I(high sensitivity cardiac troponin,hs-cTnI)、N末端脑钠肽前体(N terminal pro B type natriuretic peptide,NT-proBNP)及临床疗效、并发症发生情况.结果:观察组治疗后LVEF高于对照组,LVEDD低于对照组,差异有统计学意义(P<0.05);观察组治疗后CK-MB、hs-cTnI均低于对照组,差异有统计学意义(P<0.05);观察组治疗后NT-proBNP低于对照组,差异有统计学意义(P<0.05);观察组有效率为85.36%,对照组有效率为60.93%,观察组有效率高于对照组,差异有统计学意义(P<0.05).观察组并发症发生率与对照组比较,差异无统计学意义(P>0.05).结论:益心利水方联合人脑利钠肽可以有效改善急性心力衰竭患者心功能,降低CK-MB、hs-cTnI,降低心力衰竭标志物NT-proBNP水平.
An Analysis of the Efficacy of Heart-Boosting and Diuresis-Inducing Decoction Combined with Recombinant Human Brain Natriuretic Peptide on Acute Heart Failure
Objective:To observe the clinical efficacy of Heart-Boosting and Diuresis-Inducing Decoction combined with recombinant hu-man brain natriuretic peptide on acute heart failure.Methods:A total of 82 patients with acute heart failure who were treated in the De-partment of Geriatrics of Zhengzhou Ninth People's Hospital from June 2021 to June 2023 were selected and divided into the control group and the observation group according to the random number table method,with 41 cases in each group.The control group was given intravenous injection of recombinant human brain natriuretic peptide,while the observation group was given self-made Heart-Boosting and Diuresis-Inducing Decoction on the basis of the control group.The changes in cardiac function[including ventricular ejection frac-tion(LVEF),left ventricular end diastolic dimension(LVEDD)],creatine kinase isoenzymes-MB(CK-MB),high sensitivity cardiac troponin I(hs-cTnI),N terminal pro B type natriuretic peptide(NT-proBNP)before and after treatment,clinical efficacy and compli-cations of the two groups were observed.Results:After treatment,the LVEF in the observation group was higher than that in the control group,while the LVEDD was lower than that in the control group,with statistically significant differences(P<0.05);the CK-MB and hs-cTnI in the observation group were lower than those in the control group,with statistically significant differences(P<0.05);the NT-proBNP in the observation group was lower than that in the control group,with a statistically significant difference(P<0.05).The ef-fective rate of the observation group was 85.36%,while that of the control group was 60.93%,the effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).However,there wasnosignif-icant difference in the incidence of complications between the two groups(P>0.05).Conclusion:Heart-Boosting and Diuresis-Indu-cing Decoction combined with recombinant human brain natriuretic peptide can effectively improve the cardiac function of patients with acute heart failure,reduce CK-MB,hs-cTnI,and the level of heart failure marker NT-proBNP.
acute heart failureHeart-Boosting and Diuresis-Inducing Decoctionrecombinant human brain natriuretic peptidecardiac functionN-terminal pro-brain natriuretic peptide
国家科技期刊平台
NSTL
万方数据
维普
